€1M Seed Round – IANUMIND: AI + Biosignals for Measurable Stress Management

The opportunity
More than half of European workers report symptoms of stress, anxiety or burnout. This drives absences and turnover, and presenteeism costs companies even more than absenteeism. Coaching works, but it is expensive, hard to scale and rarely measured objectively. IANUMIND closes this gap.

The solution
IANUMIND is a phygital platform that combines QUI, a proprietary wearable sensor, with a patent-pending affective AI model developed over 10+ years of R&D with a global industrial partner, and with certified human coaches. It reads stress-related biosignals in real time and guides users through personalised, neuroscience-backed regulation techniques. Support comes 24/7 from an AI virtual coach, alongside live sessions with human coaches.

Business model
Hybrid B2B2C. Corporate workshops and 4-week pilots, delivered with partner coaches, create a channel to individual users, who then buy the QUI device (€99 one-off) and a premium subscription (€19–25/month), plus in-app content. Coaches act as commercial partners (10% commission) and as content creators (5% royalties), which keeps acquisition costs low and builds a scalable distribution network.

Traction

• TRL7 MVP in pre-sales with a professional target.

• 4 active coach partners, with 11 more in negotiation.

• A corporate workshop with a pharmaceutical company (NPS 8.5/10).

• A proof of concept completed with a systems integrator.

• 3 integrated stress management techniques, 1 under exclusive licence.

Market
The global corporate wellness market was worth $70.7B in 2024 and is expected to reach $128.2B by 2033 (IMARC Group). In Europe we estimate a €50B TAM, with a €31B SAM across 8 target countries.

The ask
We are raising €1M to reach product-market fit. The funds will be split as follows:

• 46.8% to go-to-market execution and coach community growth

• 37.4% to operations, including manufacturing, pilots and product certification

• 15.8% to Tech/Product dev (Platform & AI models are covered by Smart&Start grant by Invitalia).

Key 24-month milestones are 100 pre-ordered devices, a 24/7 AI coach, 4 completed B2B pilots, the first B2B contracts, and more than 10 active corporate clients. In our conservative scenario we break even in Q1 of year 3 and reach €12M cumulative revenues by year 5. A €3M Series A would accelerate the scale-up.

Team
Founded by Luca Ascari (CEO) and Francesca Sernissi (CBO), with medical-device and AI know-how through our subsidiary Henesis.